Clinical Trials

Cohort A* (closed): Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically
confirmed PD-L1 TPS ≥ 1%.

- Cohort C: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologically confirmed PD-L1 TPS < 50% AND previously completed 4 cycles of standard-of-care platinum based induction
chemotherapy with pembrolizumab AND experienced stable disease, partial response, or complete response per investigator's assessment after 4 cycles OR if patients received < 4 cycles of a platinum-based induction, was stopped early due to intolerable toxicity
- Cohort E: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologically confirmed PD-L1 TPS < 50%
- Presence of measurable disease per RECIST v1.1

Exclusion Criteria:

- All Cohorts: Any prior therapy targeting KRASG12C mutation in any setting
- Cohorts A & E: Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy
(note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was >1 year prior to
first dose of study treatment)
- Cohort C: received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following
completion of 4-6 cycles of a platinum-based regimen administered in the first-line
setting
- Radiation to the lung > 30 Gy within 6 months prior to first dose of study treatment
- Active brain metastases

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/5/2024. Questions regarding updates should be directed to the study team contact.